Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment.

Ther Adv Med Oncol · 2021 · PMC8669877 · PMID 34917175

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

These patients were reported to exhibit a worse OS (median OS: 23.0 months vs 33.3 months), though the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.